| Bioactivity | Maprotiline is a highly selective noradrenergic reuptake blocker, has strong antidepressant efficacy. Maprotiline induces cancer cells apoptosis by targeting ERK signaling pathway and CRABP1. Maprotiline restrains cell proliferation and metastasis, exhibits anticancer effect[1][2]. |
| Invitro | Maprotiline (10 μM) enhances the sensitivity of HCC cells to sorafenib (2 μM) and induces apoptosis[2].Maprotiline (0, 10, or 20 μM for 72 h) works on ERK pathway and inhibits phosphorylation of SREBP2 in HepG2 and Huh7 cells[2].Maprotiline may target CRABP1 and regulate cholesterol biosynthesis in HCC cells[2]. Cell Invasion Assay[2] Cell Line: |
| In Vivo | Maprotiline (3, 10, or 30 mg/kg; i.p.) combinds with the synthetic cannabinoid WIN 55,212-2 and effectively reduces neuropathic pain[1].Maprotiline (0, 20, or 40 mg/kg; i.p.; twice a week; 3 weeks) shows low toxicity and side effects on the organs, immune system and hematopoietic function[2].Maprotiline (0, 20, or 40 mg/kg; i.p.; twice a week; 3 weeks) restrains cholesterol biosynthesis to inhibit growth and metastasis of HCC cells by interacting with CRABP1[2]. Animal Model: |
| Name | Maprotiline |
| CAS | 10262-69-8 |
| Formula | C20H23N |
| Molar Mass | 277.40 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Gunduz O, et al. Analysis of the anti-allodynic effects of combination of a synthetic cannabinoid and a selective noradrenaline re-uptake inhibitor in nerve injury-induced neuropathic mice. Eur J Pain. 2016 Mar. 20(3):465-71. [2]. Zheng C, et al. Maprotiline Suppresses Cholesterol Biosynthesis and Hepatocellular Carcinoma Progression Through Direct Targeting of CRABP1. Front Pharmacol. 2021 May 20. 12:689767. |